April 14th is a landmark date in the history of Villas Boas Radiofármacos.

It was on this day, 17 years ago, that the company produced and delivered the first dose of FDG from a private facility in Brazil. Since then, nuclear medicine in the country has advanced consistently, with the expansion of PET/CT, the entry of new operators, and the incorporation of new molecules.

A milestone that helps gauge the transformation the sector has undergone — and one that continues to point toward a path of continuous evolution.